Clinical Trial: CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07443137) titled 'CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)' on Feb. 24.

Brief Summary: This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line treatment (EOT), as defined by positive measurable residual disease detected by Foresight CLARITY (PhasED-seq). Participants will initially be pre-screened for MRD status after first line treatment (1L) with chemoimmunotherapy including a CD20 monoclonal antibody and anthracycline.

Study Start Date: May, ...